1-20 of 112
Michelle A. Fanale
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

PET4 Response As an Independent Predictor of Long-Term Outcomes in ECHELON2 (A+CHP Vs. CHOP) in CD30+PTCL

Swami P. Iyer, Neha Mehta-Shah, Ranjana H. Advani, Nancy L. Bartlett, Jacob Haaber Christensen, Frank Morschhauser, EVA Domingo Domenech, Chiara Pagani, Won Seog Kim, Onder Alpdogan, Cheolwon Suh, Tatyana Feldman, Hervé Tilly, Pier Luigi Zinzani, Alessandro Rambaldi, David Belada, Jiri Mayer, Ilseung Choi, June-Won Cheong, Shweta Jain, Fenton Keenan, Michelle A. Fanale, Kerry J. Savage, Steven M. Horwitz
Journal: Blood
Blood (2023) 142 (Supplement 1): 3074.
https://doi.org/10.1182/blood-2023-184933
Published: 2023
Journal Articles

Brentuximab Vedotin, Nivolumab, Doxorubicin, and Dacarbazine for Advanced Stage Classical Hodgkin Lymphoma: Efficacy and Safety Results from the Single Arm Phase 2 Study

Hun Ju Lee, Ian W. Flinn, Jason Melear, Rod Ramchandren, Judah Friedman, John M. Burke, Yuliya Linhares, Paul Alan Gonzales, Mihir Raval, Rangaswamy Chintapatla, Tatyana Feldman, Habte A. Yimer, Miguel Islas-Ohlmayer, Asad Dean, Vishal Rana, Mitul Gandhi, John Scott Renshaw, Linda Ho, Michelle A. Fanale, Wenchuan Guo, Chris Yasenchak
Journal: Blood
Blood (2023) 142 (Supplement 1): 608.
https://doi.org/10.1182/blood-2023-173972
Published: 2023
Journal Articles

Real-World Treatment Patterns and Clinical Outcomes with Brentuximab Vedotin or Other Standard Therapies in Patients with Previously Treated Cutaneous T-Cell Lymphoma (CTCL): A Retrospective Chart Review Study in the United States

Stefan K. Barta, Nicholas Liu, Maral DerSarkissian, Rose Chang, Mingchen Ye, Mei Sheng Duh, Andy Surinach, Michelle A. Fanale, Kristina S. Yu
Journal: Blood
Blood (2022) 140 (Supplement 1): 5167–5169.
https://doi.org/10.1182/blood-2022-162375
Published: 2022
Journal Articles

Economic Burden of Hematopoietic Cell Transplantation (HCT) Among Commercially Insured Patients with Hematological Malignancies in the United States (US)

Mayur Narkhede, Nicholas Liu, Andy Surinach, Michelle A. Fanale, Kristina S. Yu, Allison Winter
Journal: Blood
Blood (2022) 140 (Supplement 1): 10798–10800.
https://doi.org/10.1182/blood-2022-162603
Published: 2022
Journal Articles

Brentuximab Vedotin, Nivolumab, Doxorubicin, and Dacarbazine (AN+AD) for Advanced Stage Classic Hodgkin Lymphoma: Updated Efficacy and Safety Results from the Single-Arm Phase 2 Study (SGN35-027 Part B)

Hun Lee, Ian W. Flinn, Jason Melear, Rod Ramchandren, Judah Friedman, John M. Burke, Yuliya Linhares, Paul Alan Gonzales, Mihir Raval, Rangaswamy Chintapatla, Tatyana Feldman, Habte Yimer, Miguel Islas-Ohlmayer, Asad Dean, Vishal Rana, Mitul Gandhi, John Renshaw, Linda Ho, Michelle A. Fanale, Wenchuan Guo, Christopher A. Yasenchak
Journal: Blood
Blood (2022) 140 (Supplement 1): 763–765.
https://doi.org/10.1182/blood-2022-156553
Published: 2022
Journal Articles

Real-World Patient Characteristics, Treatment Patterns, and Outcomes in Patients with Stage III/IV Classic Hodgkin Lymphoma Treated with Frontline ABVD: A Retrospective Analysis Using a Real-World Database

Allison Winter, Nicholas Liu, Andy Surinach, Michelle A. Fanale, Kristina S. Yu, Mayur Narkhede
Journal: Blood
Blood (2022) 140 (Supplement 1): 8054–8055.
https://doi.org/10.1182/blood-2022-162556
Published: 2022
Journal Articles

Classical Hodgkin Lymphoma; Real-World Observations from Physicians, Patients, and Caregivers on the Disease and Its Treatment (CONNECT)-a Cross-Sectional Survey of Patients with Stage III or IV Classical Hodgkin Lymphoma Compared By Age

Darcy R. Flora, Susan K. Parsons, Nicholas Liu, Kristina S. Yu, Katie Holmes, Carlos Flores, Michelle A. Fanale, Supriya Kumar, Andy Surinach, Rachel Byrd, Andrew M. Evens
Journal: Blood
Blood (2021) 138 (Supplement 1): 1966.
https://doi.org/10.1182/blood-2021-147354
Published: 2021
Journal Articles

An Oncology Simulation Model to Estimate 10-Year Progression-Free Survival and Stem Cell Transplantation for Frontline, Stage III or IV Classical Hodgkin Lymphoma Based on the 5-Year Update of the ECHELON-1 Trial: A United States Perspective

Tycel Phillips, Kristen Migliaccio-Walle, Kristina S. Yu, Brian Bloudek, Nicholas Liu, Michelle A. Fanale, John M. Burke
Journal: Blood
Blood (2021) 138 (Supplement 1): 2440.
https://doi.org/10.1182/blood-2021-147308
Published: 2021
Journal Articles

Brentuximab Vedotin, Nivolumab, Doxorubicin, and Dacarbazine (AN+AD) for Advanced Stage Classic Hodgkin Lymphoma: Preliminary Safety Results from the Single-Arm Phase 2 Study (SGN35-027 Part B)

Hun Ju Lee, Ian W. Flinn, Jason Melear, Rod Ramchandren, Judah Friedman, John M. Burke, Yuliya Linhares, Matthew R. Peterson, Mihir Raval, Rangaswamy Chintapatla, Tatyana A. Feldman, Habte Yimer, Miguel Islas-Ohlmayer, Asad Dean, Vishal Rana, Mitul D. Gandhi, John Renshaw, Amanda L. Gillespie-Twardy, Linda Ho, Michelle A. Fanale, Wenchuan Guo, Christopher A. Yasenchak
Journal: Blood
Blood (2021) 138 (Supplement 1): 2454.
https://doi.org/10.1182/blood-2021-147891
Published: 2021
Journal Articles

An Oncology Simulation Model to Estimate 10-Year Progression-Free Survival and Overall Survival Based on the 5-Year Update from the ECHELON-2 Trial in Frontline Patients with Peripheral T-Cell Lymphoma: A United States Perspective

John M. Burke, Kristina S. Yu, Uche Mordi, Brian Bloudek, Nicholas Liu, Michelle A. Fanale, Tycel Phillips
Journal: Blood
Blood (2021) 138 (Supplement 1): 2466.
https://doi.org/10.1182/blood-2021-148004
Published: 2021
Journal Articles

Classical Hodgkin Lymphoma; Real-World Observations from Physicians, Patients, and Caregivers on the Disease and Its Treatment (CONNECT): Physician First-Line Treatment Preferences for Stage III or IV Classical Hodgkin Lymphoma

Andrew M. Evens, Kristina S. Yu, Nicholas Liu, Andy Surinach, Katie Holmes, Carlos Flores, Supriya Kumar, Michelle A. Fanale, Darcy R. Flora, Susan K. Parsons
Journal: Blood
Blood (2021) 138 (Supplement 1): 2467.
https://doi.org/10.1182/blood-2021-152497
Published: 2021
Journal Articles

Classical Hodgkin Lymphoma; Real-World Observations from Physicians, Patients, and Caregivers on the Disease and Its Treatment (CONNECT): Observations of Physicians on Treatment and Interim PET-Adapted Regimens

Susan K. Parsons, Kristina S. Yu, Nicholas Liu, Supriya Kumar, Michelle A. Fanale, Katie Holmes, Carlos Flores, Andy Surinach, Darcy R. Flora, Andrew M. Evens
Journal: Blood
Blood (2021) 138 (Supplement 1): 1390.
https://doi.org/10.1182/blood-2021-151143
Published: 2021
Journal Articles

Prognostic Factors Other Than Age Drive the Risk of Disease Progression in Adults with Burkitt Lymphoma Treated with DA-EPOCH-R

Rahul Lakhotia, Kieron Dunleavy, Jeremy S. Abramson, Brian K. Link, Bayard L. Powell, Christopher Melani, Andrea Nicole Lucas, Seth M. Steinberg, Jonathan W. Friedberg, Brad S. Kahl, Richard F. Little, Nancy L. Bartlett, Michelle A. Fanale, Ariela Noy, Wyndham H. Wilson, Mark Roschewski
Journal: Blood
Blood (2021) 138 (Supplement 1): 453.
https://doi.org/10.1182/blood-2021-147451
Published: 2021
Journal Articles

The Echelon-2 Trial: 5-Year Exploratory Subgroup Analyses of a Randomized, Double-Blind, Phase 3 Study of Brentuximab Vedotin and CHP (A+CHP) Vs CHOP in Frontline Treatment of Pts with CD30-Positive Peripheral T-Cell Lymphoma

Steven M. Horwitz, Kerry J. Savage, Tim Illidge, Swaminathan P Iyer, Ranjana Advani, Andrei R Shustov, Nancy L. Bartlett, Barbara Pro, Eric D Jacobsen, Raphael Koch, Domingo Domenech Eva, Michelle A. Fanale, Keenan Fenton, Frank Campana, Cassie Dong, Lorenz Truemper
Journal: Blood
Blood (2021) 138 (Supplement 1): 135.
https://doi.org/10.1182/blood-2021-145124
Published: 2021
Journal Articles

Brentuximab Vedotin with Chemotherapy for Patients with Previously Untreated, Stage III/IV Classical Hodgkin Lymphoma: 5-Year Update of the ECHELON-1 Study

David J. Straus, MD, Monika Dlugosz-Danecka, MD PhD, Joseph M. Connors, MD, Árpád Illés, MD PhD, Marco Picardi, MD, Ewa Lech-Marańda, MD PhD, Tatyana Feldman, Piotr Smolewski, MD PhD, Kerry J. Savage, MDMSc, Nancy L. Bartlett, MD, Jan Walewski, MD, Radhakrishnan Ramchandren, MD, Pier Luigi Zinzani, MD, Martin Hutchings, MD PhD, Javier Munoz, MD, Won Seog Kim, MD PhD, Ranjana Advani, MD, Stephen M. Ansell, MD PhD, Anas Younes, Andrea Gallamini, Rachael Liu, PhD, Meredith Little, MPH, Keenan Fenton, Michelle A. Fanale, MD, John A. Radford, MD FMedSci
Journal: Blood
Blood (2020) 136 (Supplement 1): 26–28.
https://doi.org/10.1182/blood-2020-137089
Published: 2020
Journal Articles

Real-World Adherence to National Comprehensive Cancer Network (NCCN) Guidelines Regarding the Usage of PET/CT and Reported Deauville Scores in Advanced Stage Classical Hodgkin Lymphoma: A Community Oncology Practice Perspective

Christopher A. Yasenchak, MD, Jamyia Clark, PhD MPH, Nicholas Liu, PharmD, April Beeks, MPH, Michelle A. Fanale, MD, Nicholas Robert, MDM, Kristina Yu-Isenberg, PhD MPH, RPh
Journal: Blood
Blood (2020) 136 (Supplement 1): 32–33.
https://doi.org/10.1182/blood-2020-140698
Published: 2020
Journal Articles

Nivolumab Combined with Brentuximab Vedotin for Relapsed/Refractory Mediastinal Gray Zone Lymphoma: Primary Efficacy and Safety Analysis of the Phase 2 CheckMate 436 Study

Armando Santoro, Alison J. Moskowitz, MD, Silvia Ferrari, MD, Carmelo Carlo-Stella, MD, Michelle A. Fanale, MD, Stephen Francis, Mariana Sacchi, MD, Kerry J. Savage, MDMSc
Journal: Blood
Blood (2020) 136 (Supplement 1): 44–45.
https://doi.org/10.1182/blood-2020-137653
Published: 2020
Journal Articles

Real-World Characteristics of Patients with Classical Hodgkin Lymphoma Receiving Frontline Brentuximab Vedotin with Chemotherapy: A Retrospective Analysis with Propensity Score Matching

Tycel J. Phillips, MD, Kristina Yu-Isenberg, PhD MPH, RPh, Nicholas Liu, PharmD, Andy Surinach, MPH, Carlos Flores, MPH, Julie Lisano, PharmD, Michelle A. Fanale, MD, John M. Burke, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 3–4.
https://doi.org/10.1182/blood-2020-140534
Published: 2020
Journal Articles

Real-World Characteristics of Patients with Peripheral T-Cell Lymphoma Receiving Frontline Brentuximab Vedotin with Chemotherapy: A Retrospective Analysis with Propensity Score Matching

John M. Burke, MD, Nicholas Liu, PharmD, Kristina Yu-Isenberg, PhD MPH, RPh, Michelle A. Fanale, MD, Andy Surinach, MPH, Carlos Flores, MPH, Julie Lisano, PharmD, Tycel J. Phillips, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 18–19.
https://doi.org/10.1182/blood-2020-140832
Published: 2020
Journal Articles

The Echelon-2 Trial: 5-Year Results of a Randomized, Double-Blind, Phase 3 Study of Brentuximab Vedotin and CHP (A+CHP) Versus CHOP in Frontline Treatment of Patients with CD30-Positive Peripheral T-Cell Lymphoma

Steven M. Horwitz, MD, Owen A. O'Connor, MD, Barbara Pro, MD, Tim Illidge, MD PhD, Swami P. Iyer, MD, Ranjana Advani, MD, Nancy L. Bartlett, MD, Jacob Haaber Christensen, Franck Morschhauser, MD, Eva Domingo-Domenech, MD, Giuseppe Rossi, MD, Won Seog Kim, PhD, Tatyana A. Feldman, MD, Tobias Menne, MD PhD, David Belada, MD PhD, Árpád Illés, MD PhD, Kensei Tobinai, MD, Kunihiro Tsukasaki, MD PhD, Su-Peng Yeh, MD, Andrei R Shustov, MD, Andreas Hüttmann, MD, Kerry J. Savage, BSc, MD MSc, Sam Yuen, MBBS, FRACP, FRCPA, Pier Luigi Zinzani, MD, Harry Miao, MD, Veronica Bunn, PhD, Keenan Fenton, MA, Michelle A. Fanale, MD, Markus Puhlmann, MD, Lorenz Truemper, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 3–5.
https://doi.org/10.1182/blood-2020-134398
Published: 2020